MERCURY LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 846 INR | -3.53% |
|
-0.34% | -17.83% |
| 02-12 | Mercury Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
| 2023 | Mercury Laboratories Names COO | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 579M 6.95M 9.45M | Sales 2023 | 753M 9.03M 12.29M | Capitalization | 702M 8.42M 11.46M |
|---|---|---|---|---|---|
| Net income 2022 | 36M 432K 587K | Net income 2023 | 55M 660K 897K | EV / Sales 2022 | 1 x |
| Net cash position 2022 | 2.49M 29.87K 40.64K | Net Debt 2023 | 20.43M 245K 333K | EV / Sales 2023 | 0.96 x |
| P/E ratio 2022 |
15.8
x | P/E ratio 2023 |
12.6
x | Employees | 537 |
| Yield 2022 |
0.72% | Yield 2023 |
0.6% | Free-Float | 14.15% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.53% | ||
| 1 week | -0.34% | ||
| Current month | -2.73% | ||
| 1 month | -9.23% | ||
| 3 months | -8.54% | ||
| 6 months | +6.27% | ||
| Current year | -17.83% |
1 week
820.00
877.00
1 month
808.00940.00
Current year
800.001 303.00
1 year
583.001 303.00
3 years
390.001 303.00
5 years
212.001 303.00
10 years
32.491 303.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 72 | 82-02-15 | |
Ashish Vasavada
DFI | Director of Finance/CFO | - | - |
Saurabh Mittal
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 72 | 82-02-15 | |
| Director/Board Member | 69 | 82-02-15 | |
| Chairman | 75 | 14-07-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-15 | 846 | -3.53% | 32 |
| 24-05-13 | 877 | +4.28% | 102 |
| 24-05-09 | 841 | -2.66% | 33 |
| 24-05-08 | 864 | +1.78% | 8 |
| 24-05-07 | 848.8 | -0.22% | 136 |
Delayed Quote Bombay S.E., May 15, 2024 at 06:00 am
More quotes
Mercury Laboratories Limited is an India-based pharmaceutical company. The Company operates through the Pharmaceuticals Products segment. The Company is engaged in the manufacturing and export of a range of pharmaceutical items. The products of the Company are in the segment of gynecology and pediatrics. Its products include antibiotic, antifungal, and antiviral formulations; anti-inflammatory formulations; antimalarial formulations; digestive formulations; hypoglycemic formulations; multivitamin formulations; central nervous system formulations; gynec formulations; CVS formulations; cough and cold formulations; and miscellaneous formulations, among others. Its antibiotic, antifungal, and antiviral formulations include azithromycin tablets, azithromycin dispersible tablets, griseofulvin tablets, metronidazole tablets, and others. Its anti-inflammatory formulations include dexamethasone tablets, glucosamine sulphate tablets, dexamethasone sodium phosphate injection, and others.
Sector
Pharmaceuticals
Calendar
2024-05-29
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -17.83% | 12.6M | |
| +15.09% | 74.45B | |
| +11.35% | 9.18B | |
| +54.35% | 5.03B | |
| -12.85% | 5.02B | |
| +1.60% | 3.82B | |
| -20.85% | 2.41B | |
| +16.88% | 2.39B | |
| -29.25% | 2.27B | |
| +24.62% | 2.26B |
- Stock Market
- Equities
- MERCURYLAB6 Stock